Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 4688 |
| PDBID: | 7QBG |
| Chains: | G_A |
| Organism: | Homo sapiens, Vicugna pacos |
| Method: | XRD |
| Resolution (Å): | 2.69 |
| Reference: | 10.1096/fj.202101376RR |
| Antibody | |
| Antibody: | TC-Nb4 Nanobody |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Transcobalamin-2 |
| Antigen mutation: | No |
| Durg Target: | |
Sequence information
Antibody
Chain: G
Mutation: NULL
| >7QBG_G|Chain E, F[auth G]|Anti-TC:CD320 nanobody TC-Nb4|Vicugna pacos (30538) QRQLVESGGGLVQPGGSLRLSCAASGFTPGIYDIGWFRQAPGKEREGVSCISSRGSSTNYADSVKGRFIISRDNVKNTVYLQMNSLEPEDTAVYYCAAIYQPSNGCVLRPEYSYWGKGTPVTVSSHHHHHHEPEA |
Antigen
Chain: A
Mutation: NULL
| >7QBG_A|Chain A, C|Transcobalamin-2|Homo sapiens (9606) EMCEIPEMDSHLVEKLGQHLLPWMDRLSLEHLNPSIYVGLRLSSLQAGTKEDLYLHSLKLGYQQCLLGSAFSEDDGDCQGKPSMGQLALYLLALRANCEFVRGHKGDRLVSQLKWFLEDEKRAIGHDHKGHPHTSYYQYGLGILALCLHQKRVHDSVVDKLLYAVEPFHQGHHSVDTAAMAGLAFTCLKRSNFNPGRRQRITMAIRTVQEEILKAQTPEGHFGNVYSTPLALQFLMTSPMRGAELGTACLKARVALLASLQDGAFQNALMISQLLPVLNHKTYIDLIFPDCLAPRVMLEPAAETIPQTQEIISVTLQVLSLLPPYRQSISVLAGSTVEDVLKKAHELGGFTYETQASLSGPYLTSVMGKAAGEREFWQLLRDPNTPLLQGIADYRPKDGETIELRLVSW |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| G: GLY47 THR49 ILE52 TYR53 GLU65 ARG75 TYR121 GLN122 PRO123 SER124 ASN125 GLY126 VAL128 ARG130 GLU132 TYR133 SER134 TYR135 TRP136 A: GLN64 CYS65 LEU66 LEU67 GLY68 CYS78 GLY80 LYS81 PRO82 MET84 ARG108 GLN112 TRP115 PHE116 ASP119 ARG122 ALA123 HIS133 GLN355 GLY368 LYS369 ALA370 GLU373 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
